
Beijing Tong Ren Tang Co., Ltd.
Beijing Tong Ren Tang Co., Ltd. is China's oldest and most culturally significant pharmaceutical brand, founded in 1669 during the Qing Dynasty under the reign of Emperor Kangxi. Listed on the Shanghai Stock Exchange (600085.SH) and Hong Kong Exchange (3613.HK), the group generated CNY 17.26 billion in revenue in 2025, a decline of 7.2% year-on-year amid challenging macroeconomic conditions and surging raw material costs. Despite short-term financial headwinds, Tong Ren Tang retains unparalleled brand prestige globally, particularly in emergency cardiovascular care, sedative/anxiolytic treatments, and premium tonic preparations such as An Gong Niu Huang Wan and Tong Ren Niuhuang Qingxin Wan. The group's international retail network spans dozens of countries through its Hong Kong-listed platform and direct-operation TCM clinics.
Strengths: (1) Unmatched 355-year brand heritage creating irreplaceable consumer trust in premium TCM; (2) Exclusive pricing power in high-margin emergency and neurological preparations; (3) Global distribution network covering Southeast Asia, North America, and Europe serving overseas Chinese communities; (4) Strong diversification into national trend health beverages and AI-powered digital retail transformation; (5) Premium market positioning insulated from centralized procurement (VBP) pressure through private retail channels.
Weaknesses: (1) Severe Q4 2025 profit decline of 93.3% due to rare medicinal herb cost volatility; (2) Revenue contraction of 7.2% reflects structural challenges in legacy product portfolios; (3) Heavy dependency on traditional high-margin products creates risk if consumer preferences shift.Read More ▼Show Less ▲
Strengths: (1) Unmatched 355-year brand heritage creating irreplaceable consumer trust in premium TCM; (2) Exclusive pricing power in high-margin emergency and neurological preparations; (3) Global distribution network covering Southeast Asia, North America, and Europe serving overseas Chinese communities; (4) Strong diversification into national trend health beverages and AI-powered digital retail transformation; (5) Premium market positioning insulated from centralized procurement (VBP) pressure through private retail channels.
Weaknesses: (1) Severe Q4 2025 profit decline of 93.3% due to rare medicinal herb cost volatility; (2) Revenue contraction of 7.2% reflects structural challenges in legacy product portfolios; (3) Heavy dependency on traditional high-margin products creates risk if consumer preferences shift.
Business Nature
Core Business Areas
Industry Rankings
Corporate Report
VerityRank Score
Based on market presence, financial scale, operational capacity, and brand strength.
Quick Facts
Headquarters
Beijing
Founded
1669
Employees
17,000
Factories
Beijing, China; Hong Kong (overseas distribution hub)
Listing
Listed - SSE (600085.SH), HKEX (3613.HK)
Categories
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website , Tongrentang 2025 Annual Report - Futunn, Annual Report 2025 - Beijing Tong Ren Tang, Beijing Tongrentang - Wikimedia Commons
